EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Multizentrische Studie

Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial

Jose M Miro, Ferran Torres, Christian Manzardo, Eva Bonfill, Adrià Curran, Pere Domingo, Daniel Podzamczer, Roger Paredes, Lluis Force, Vicenç Falco, Mar Gutierrez, Maria Saumoy und 9 weitere

Clinical Microbiology and Infection · 2026

DOI: 10.1016/j.cmi.2025.09.026 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Jose M Miro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service, Hospital Clínic-Fundació Recerca Clinic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBA…. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 3-Ring, Darunavir, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Departament de Salut, Generalitat de Catalunya, ViiV Healthcare UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG) vs. darunavir (DRV) boosted-based antiretroviral (ART) regimens in very advanced HIV patients. METHODS: Phase IV, randomized (1:1 ratio), open-label trial, including adult (≥18 years) ART-naïve HIV-1+ patients with CD4+ cell counts 200 cells/μL. Of the patients, 41 (78.8%) and 31 (63.3%) (p 0.1229) in the DTG and DRV/r arms, respectively, achieved undetectable viral loads at 48 weeks; differences were significant at weeks 4 (p < 0.0001) and 12 (p 0.0009). Inflammation and bacterial translocation markers decreased more in the DTG arm, median (IQR) -8 (-11, -4) vs. -5 (-9, -3) pg/mL (p 0.0357) and -972 (-1334, -508) vs. -544 (-1128, -292) μg/mL (p 0.0565), respectively, at 48 weeks. Discontinuation rates were higher in the DRV/r arm (3/52 (5.8%) vs. 9/51 (18.4%); p 0.0526). CONCLUSIONS: DTG/3TC/ABC is safe and efficacious in very advanced ART-naïve HIV + patients, induced a faster virologic response, and was superior to the DRV/r regimen in reducing inflammation and bacterial translocation markers at 48 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHeterocyclic Compounds, 3-RingDarunavirAnti-HIV AgentsHumansMaleOxazinesFemaleAdultPyridonesPiperazinesMiddle AgedCD4 Lymphocyte CountViral LoadAntiretroviral Therapy, Highly ActiveHIV-1LamivudineTreatment OutcomeSpainRitonavirDolutegravir

Stichwörter der Autor:innen

AIDSBacterial translocationDarunavir/ritonavirDolutegravirHIVImmune reconstitutionInflammation markersNaïve patientsRandomized clinical trialVery advanced HIV

Substanzen

Heterocyclic Compounds, 3-RingOxazinesDarunavirPyridonesPiperazinesAnti-HIV AgentsLamivudineRitonavirDolutegravir

Autor:innen und Institutionen

  • Infectious Diseases Service, Hospital Clínic-Fundació Recerca Clinic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; Centro de Investigació…
  • Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona, Barcelona, Spain; Medical Statistics Core Facility, Hospital Clínic-IDIBAPS, Barcelona, Spain.
  • Infectious Diseases Service, Hospital Clínic-Fundació Recerca Clinic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Clinical Trials Unit, Hospital Clínic-Fundació Recerca Clinic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
  • Infectious Diseases Service, Hospital Universitari Vall d'Hebron-Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • HIV Unit, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.

Förderung

  • Departament de Salut, Generalitat de Catalunya
  • ViiV Healthcare UK

Zitieren

APA

Miro, J. M., Torres, F., Manzardo, C., Bonfill, E., Curran, A., Domingo, P., Podzamczer, D., Paredes, R., Force, L., Falco, V., Gutierrez, M., Saumoy, M., Castelli, A., Inciarte, A., Rovira, C., Cruceta, A., Hurtado, C., Climent, N., Lozano, F., …, & Advanz-4 investigators (2026). Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.09.026

Vancouver

Miro JM, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, et al. Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2025.09.026

BibTeX
@article{Miro2026,
  author = {Miro, Jose M and Torres, Ferran and Manzardo, Christian and Bonfill, Eva and Curran, Adrià and Domingo, Pere and Podzamczer, Daniel and Paredes, Roger and Force, Lluis and Falco, Vicenç and Gutierrez, Mar and Saumoy, Maria and Castelli, Anna and Inciarte, Alexy and Rovira, Cristina and Cruceta, Anna and Hurtado, Carmen and Climent, Núria and Lozano, Francisco and Plana, Montserrat and Advanz-4 investigators, Advanz-4 investigators},
  title = {Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial},
  journal = {Clinical Microbiology and Infection},
  year = {2026},
  doi = {10.1016/j.cmi.2025.09.026}
}
Kostenlos starten →